How The DocGo (DCGO) Story Is Shifting As Transport Optimism Meets Lower Valuation Targets

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

DocGo’s modeled fair value was revised from US$2.10 to US$1.87, a change that puts a sharper focus on what analysts think the stock is worth today. Recent Street commentary ties this reset to both optimism around the transport business and caution around execution, with some price targets, such as US$2.50, reflecting that mixed view. As you read on, you will see how these shifting targets and assumptions are shaping the evolving narrative around the stock and what that could mean for your own research.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value DocGo.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Stifel trimmed its DocGo price target to US$2.50 from US$4 but kept a Buy rating, which signals the firm still sees upside potential at current levels despite recent adjustments. Stifel highlights the transport segment as a key positive, pointing to 2026 guidance that was raised modestly and to analyst estimates that this unit could generate US$15m to US$20m of 2026 EBITDA before overhead. According to Stifel, the potential EBITDA from transport alone could imply proceeds above the current share price, which keeps that segment central to many bullish valuation arguments.

🐻 Bearish Takeaways

Both Stifel and Canaccord have lowered their price targets, which reflects a reset in expectations and a more cautious stance around execution and near term performance. Stifel describes DocGo’s Q4 results as mixed, which can raise questions for some investors about consistency of results even as certain segments, such as transport, show areas of strength.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqCM:DCGO 1-Year Stock Price Chart

We've flagged 2 risks for DocGo. See which could impact your investment.

What's in the News

DocGo updated its full year 2026 revenue guidance to a range of US$300 million to US$315 million, compared with prior ranges of US$290 million to US$310 million and initial guidance of US$280 million to US$300 million. The company also provided 2026 revenue guidance of US$290 million to US$310 million that excludes any migrant-related revenue, compared with earlier guidance of US$280 million to US$300 million. DocGo reported that from October 1, 2025 to December 31, 2025 it repurchased 0 shares, and that it has completed total buybacks of 5,476,840 shares, or 5.42%, for US$14.69 million under its existing program. The company is asking stockholders to vote on proposals at the June 16, 2026 annual meeting, including a possible reverse stock split in a ratio between 1-for-5 and 1-for-10, proportional reductions in authorized shares, a waiver of certain corporate opportunities, and expanded officer liability protections.

Story Continues

How This Changes the Fair Value For DocGo

Modeled fair value moved from US$2.10 to US$1.87 per share. Revenue growth assumption shifted from a 0.56% decline to 4.18% growth. Profit margin assumption changed from 5.12% to 6.08%. Future P/E multiple moved from 15.38x to 10.84x. Discount rate changed from 6.98% to 7.33%.

Never Miss an Update: Follow The Narrative

Narratives connect DocGo’s business story to analyst assumptions about growth, margins, and risk, and link that story to a fair value estimate. They refresh as new earnings, guidance, and contract updates come through, so you can see how the thesis evolves over time.

Head over to the Simply Wall St Community and follow the Narrative on DocGo to stay up to date on:

How expansion into at home care, gap closure, and primary care programs with major payers could shape DocGo’s longer term revenue mix. The role of technology, AI tools, and logistics platforms in improving clinician utilization, patient engagement, and Mobile Health and transport efficiency. Key risks from the wind down of high margin migrant contracts, thin transport margins, and exposure to large government and health system contracts that may affect revenue stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DCGO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments